性传染病自我检测市场－全球产业规模、份额、趋势、机会、预测：按应用、区域和竞争格局划分，2021-2031年

全球性行为感染(STI) 自检市场预计将从 2025 年的 12.9 亿美元成长到 2031 年的 20.2 亿美元，复合年增长率达到 7.76%。

该市场涵盖允许个人私密采集生物检体并即时获得结果或进行后续检查室分析的诊断产品。推动该市场发展的主要因素是性行为感染传染病的蔓延，这使得人们对便捷、易用的筛检方法产生了迫切需求。此外，消费者对隐私日益增长的需求，以及远端医疗服务的无缝整合，也促进了这些便捷检测方案的广泛接受和应用。

根据美国性健康协会发布的2025年报告，上年度美国报告的性行为感染感染病例约有220万例。儘管市场需求强劲，但家用诊断试剂盒严格的监管环境严重阻碍了市场成长。卫生部门始终将确保未经训练的使用者所采集的检体的准确性放在首位，而这项担忧也限制了消费性新核准速度。

市场驱动因素

性行为感染感染（STI）在全球范围内的日益蔓延是推动性传染病自检市场发展的主要因素，也使得便利的筛检工具成为一项重要的公共卫生需求。随着不同人群感染率的上升，传统的诊所检测机构不堪重负，促使人们转向私人的、用户主导的诊断​​方式。这种趋势在弱势群体中尤其明显，因为诸如社会歧视和预约限制等障碍阻碍了他们及时获得诊断。例如，欧洲疾病预防控制中心（ECDC）在2025年12月报告称，2021年至2023年间，20至24岁女性淋病报告率增长了约200%，这凸显了在临床环境之外增加检测能力的必要性。

同时，越来越多的家用诊断设备获得监管机构核准，解决了人们对检测可靠性和检体准确性的传统担忧，从而推动了市场发展。监管机构正在扩大对无需处方笺即可提供检查室层级检测结果的市售分子检测的批准范围，从而证实了自我检测的临床价值。例如，2025年3月，美国FDA批准了Visby Medical的女性健康检测，该检测在临床试验中检出率高达97.2%的披衣菌感染衣原体阳性检体。法规环境的这种变化缓解了人们对安全性的担忧，并促进了其更广泛的应用。此外，美国疾病管制与预防中心（CDC）2025年的数据显示，约有4000例先天性梅毒病例，凸显了早期发现对于避免严重健康损害的关键作用。

市场挑战

严格的居家检测法规结构对全球性行为感染）自检市场的扩张构成重大障碍。卫生部门制定了严格的标准，以确保使用者自行采集的检体检测结果与专业医护人员采集的样本具有相同的临床可靠性。这项要求迫使製造商在非受控环境下进行全面且高成本的可用性研究，以检验检体灵敏度和检体完整性，从而显着延长核准流程并增加市场准入所需的资本投入。

监管审批的延误直接阻碍了市场成长，限制了已通过核准产品的供应，而随着全球感染疾病负担的持续加重，这无疑是一个严峻的问题。缓慢的核准流程限制了业界满足公众对便利筛检方法的迫切需求的能力。根据世界卫生组织（世卫组织）2024年的数据，四种可治疗的性行为感染感染每天在全球造成超过一百万例新增感染。感染率的激增与符合监管规定的自检解决方案部署的延误之间的差距，造成了供需缺口，限制了收入潜力，并减缓了这些技术的普及应用。

市场趋势

远端医疗和数位健康平台的融合正在重塑市场，建构一个超越单纯诊断的综合医疗生态系统。越来越多的自测产品包含虚拟咨询和电子处方笺服务，确保检测结果呈阳性者能及时获得医疗救治。这种方式不仅能减轻患者的焦虑，还能透过远距管理无症状感染者来缓解实体医疗系统的负担。这项转变凸显了人们对数位化性健康服务日益增长的需求，爱尔兰卫生署的数据也印证了这一点：2024年，该机构共出货126,090套家用性性行为感染检测套组。

同时，医生主导的直接面向消费者（CDM）销售模式的兴起，绕过了传统的检查室流程，使更多人能够获得临床级别的诊断。製造商正大力投资扩大生产规模并建立直销管道，使消费者无需事先进行面对面咨询即可购买高精度分子检测。这一趋势促使企业对诊断设备的商业化策略进行大规模投资，将其作为消费健康产品进行销售。例如，根据 MobiHealthNews 2025 年 6 月报道，Visby Medical 已筹集约 5,500 万美元，用于加速其无需设备的 PCR 检测平台的直接向消费者销售。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球性传染病自检市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依申请项目（CT/NG扫描、梅毒检测、HIV检测等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美性传染病自我检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲性传染病自检市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区性传染病自检市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲性传染病自检市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美性传染病自检市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球性传染病自我检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• OraSure Technologies, Inc.
• Selfdiagnostics Deutschland GmbH
• Wondfo BIOTECH CO., LTD.
• bioLytical Laboratories Inc.
• autotest VIH Inc.
• Abbott Laboratories
• Visby Medical Inc.
• PrivaPath Diagnostics
• NOWDiagnostics Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global STD Self-Testing Market is projected to expand from USD 1.29 Billion in 2025 to USD 2.02 Billion by 2031, achieving a CAGR of 7.76%. This market encompasses diagnostic products designed to enable individuals to collect biological samples privately, either for immediate interpretation or subsequent laboratory analysis. The primary force driving this market is the increasing prevalence of sexually transmitted infections, which has generated an urgent demand for discreet and accessible screening options. Additionally, the growing consumer desire for privacy, coupled with the seamless integration of telehealth services, is bolstering the widespread acceptance and adoption of these convenient testing solutions.

According to the American Sexual Health Association in 2025, approximately 2.2 million sexually transmitted infection cases were reported in the United States during the preceding year. Despite this robust demand, market growth encounters significant obstacles due to the strict regulatory environment governing home diagnostics. Health authorities continue to prioritize ensuring the accuracy of samples collected by untrained users, a concern that restricts the pace at which new products obtain approval for general consumer usage.

Market Driver

The increasing global prevalence of sexually transmitted infections acts as the main catalyst for the STD self-testing market, creating a critical public health requirement for accessible screening tools. As infection rates rise across various demographic groups, conventional clinic-based testing facilities struggle to handle the volume, prompting a shift toward private, user-led diagnostic options. This trend is especially noticeable among vulnerable populations where barriers such as stigma and scheduling conflicts hinder timely diagnosis. For instance, the European Centre for Disease Prevention and Control reported in December 2025 that gonorrhea notification rates among women aged 20 to 24 increased by nearly 200% between 2021 and 2023, highlighting the necessity for testing capabilities beyond clinical settings.

Concurrently, the market is being propelled by an increase in regulatory approvals for at-home diagnostic devices, which are addressing historical doubts concerning test reliability and sample accuracy. Regulators are increasingly authorizing over-the-counter molecular tests that provide lab-quality outcomes without a prescription, thus confirming the clinical value of self-testing. Notably, in March 2025, the U.S. FDA authorized the Visby Medical Women's Sexual Health Test, which identified 97.2% of positive Chlamydia trachomatis samples in clinical trials. This evolving regulatory environment mitigates safety concerns and promotes broader adoption, while 2025 data from the CDC showing nearly 4,000 cases of congenital syphilis further emphasizes the vital role of early detection in averting serious health consequences.

Market Challenge

Strict regulatory frameworks regarding home-based diagnostics present a substantial barrier to the expansion of the Global STD Self-Testing Market. Health authorities enforce rigorous standards to ensure that biological samples collected by lay users produce results that are clinically equivalent to those gathered by healthcare professionals. This requirement forces manufacturers to conduct comprehensive and expensive usability studies to verify test sensitivity and sample integrity in uncontrolled settings, significantly prolonging the approval process and raising the capital investment needed for market entry.

These regulatory delays directly hinder market growth by limiting the availability of approved products, even as the global burden of infections continues to rise. The slow pace of clearance restricts the industry's capacity to meet the urgent public health need for accessible screening methods. According to the World Health Organization in 2024, four curable sexually transmitted infections were responsible for over 1 million new infections every day globally. This disconnect between the surging infection rates and the delayed introduction of compliant self-testing solutions creates a gap between supply and demand that limits revenue potential and slows the widespread adoption of these technologies.

Market Trends

The convergence of telemedicine and digital health platforms is transforming the market by establishing a comprehensive care ecosystem that extends beyond simple diagnosis. Self-testing products are increasingly being packaged with virtual consultations and electronic prescription services, ensuring that individuals testing positive receive prompt medical attention. This approach not only reduces patient anxiety but also eases the burden on physical healthcare systems by managing asymptomatic cases remotely, a shift supported by data such as the Department of Health in Ireland reporting the dispatch of 126,090 home STI test kits in 2024, indicating growing demand for digitally managed sexual health services.

In parallel, the rise of physician-mediated direct-to-consumer models is democratizing access to clinical-grade diagnostics by bypassing traditional laboratory logistics. Manufacturers are securing significant investment to expand production and build direct retail channels, enabling consumers to purchase high-accuracy molecular tests without needing an initial in-person appointment. This trend involves substantial spending on commercialization strategies that market diagnostic devices as consumer health products; for example, in June 2025, MobiHealthNews reported that Visby Medical raised roughly $55 million to expedite the direct-to-consumer launch of its instrument-free PCR testing platform.

Key Market Players

• OraSure Technologies, Inc.
• Selfdiagnostics Deutschland GmbH
• Wondfo BIOTECH CO., LTD.
• bioLytical Laboratories Inc.
• autotest VIH Inc.
• Abbott Laboratories
• Visby Medical Inc.
• PrivaPath Diagnostics
• NOWDiagnostics Inc.

Report Scope

In this report, the Global STD Self-Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

STD Self-Testing Market, By Application

• CT/NG Testing
• Syphilis Testing
• HIV Testing
• Others

STD Self-Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global STD Self-Testing Market.

Available Customizations:

Global STD Self-Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global STD Self-Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (CT/NG Testing, Syphilis Testing, HIV Testing, Others)
  • 5.2.2. By Region
  • 5.2.3. By Company (2025)
• 5.3. Market Map

6. North America STD Self-Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States STD Self-Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
  • 6.3.2. Canada STD Self-Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
  • 6.3.3. Mexico STD Self-Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application

7. Europe STD Self-Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany STD Self-Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
  • 7.3.2. France STD Self-Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
  • 7.3.3. United Kingdom STD Self-Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
  • 7.3.4. Italy STD Self-Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
  • 7.3.5. Spain STD Self-Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application

8. Asia Pacific STD Self-Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China STD Self-Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
  • 8.3.2. India STD Self-Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
  • 8.3.3. Japan STD Self-Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
  • 8.3.4. South Korea STD Self-Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
  • 8.3.5. Australia STD Self-Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application

9. Middle East & Africa STD Self-Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia STD Self-Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
  • 9.3.2. UAE STD Self-Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
  • 9.3.3. South Africa STD Self-Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application

10. South America STD Self-Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil STD Self-Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
  • 10.3.2. Colombia STD Self-Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
  • 10.3.3. Argentina STD Self-Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global STD Self-Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. OraSure Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Selfdiagnostics Deutschland GmbH
• 15.3. Wondfo BIOTECH CO., LTD.
• 15.4. bioLytical Laboratories Inc.
• 15.5. autotest VIH Inc.
• 15.6. Abbott Laboratories
• 15.7. Visby Medical Inc.
• 15.8. PrivaPath Diagnostics
• 15.9. NOWDiagnostics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer